From Biology to the Clinic: Optimizing Rationale, Development & Translation of Bispecific ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

From Biology to the Clinic: Optimizing Rationale, Development & Translation of Bispecific ADCs

2:00 pm - Tuesday 13th October 2026

Breaking down biology rationale for pursuing bispecific ADC development and selecting target pairings
Evaluating preclinical profiles of bispecific ADCs highlighting favorable efficacy and tolerability profiles against monospecific therapies
Laying out considerations and strategy to optimize successful translational through biomarker and clinical development strategies

Speakers:

Stephen huang

Stephen huang

executive director

Avenzo Therapeutics